Aims: Acute promyelocytic leukemia (APL) progresses quickly and often leads to early hemorrhagic death. Treatment with all-trans retinoic acid (ATRA) promotes differentiation of APL cells and clinical remission, making APL a potentially curable malignancy. Understanding how ATRA works may lead to new treatments for other types of leukemia. Long non-coding RNA NEAT1 has been implicated in the differentiation of APL cells. This study aims to elucidate the specific role of NEAT1 in the granulocytic differentiation of APL.

Methods: The influence of NEAT1 on autophagy and PML/RARα degradation was assessed using western blot assays. The impact of NEAT1 on the expression of autophagy-related genes was evaluated through quantitative real-time RT-PCR. Mechanistic insights into the role of NEAT1 in modulating autophagy were supported by RNA immunoprecipitation and RNA pulldown assays.

Key Findings: Knockdown of NEAT1 suppressed autophagy and attenuated ATRA-induced PML/RARα degradation and granulocytic differentiation of APL cells. Subsequent screening of autophagy-related genes demonstrated that silencing NEAT1 impaired the ATRA-induced upregulation of ATG10 and ATG12. Mechanistic investigations revealed that the RNA-binding protein TAF15 interacted with NEAT1, synergistically stabilizing the mRNA of ATG10 and ATG12. Furthermore, knockdown of NEAT1 impaired the interactions between TAF15 and the mRNAs of ATG10 and ATG12, thereby compromising their mRNA stability.

Significance: Our study elucidates the critical role of NEAT1-mediated autophagy in the differentiation of APL cells and delineates the molecular mechanism by which upregulation of NEAT1 enhances autophagy. Specifically, NEAT1 binds to the RNA-binding protein TAF15, which in turn stabilizes the mRNA of both ATG10 and ATG12.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11666005PMC
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0316109PLOS

Publication Analysis

Top Keywords

differentiation apl
16
apl cells
16
atg10 atg12
16
granulocytic differentiation
12
neat1
11
role neat1
8
pml/rarα degradation
8
autophagy-related genes
8
knockdown neat1
8
neat1 impaired
8

Similar Publications

Differentiation therapy with all-trans retinoic acid (ATRA) is well established for acute promyelocytic leukemia (APL). However, the narrow application and tolerance development of ATRA remain to be improved. A number of kinase inhibitors have been reported to induce cell differentiation.

View Article and Find Full Text PDF

Study on clinical features of early death in older patients with acute promyelocytic leukemia.

Ann Hematol

December 2024

Key Laboratory of Hepatosplenic Surgery, Ministry of Education, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, People's Republic of China.

This study aimed to analyze the baseline clinical characteristics, as well as the clinical features and risk factors of early death (ED) in older patients with acute promyelocytic leukemia (APL). A retrospective analysis was conducted on 198 consecutive older patients (age ≥ 50 years) with newly diagnosed APL who received arsenic trioxide alone as induction therapy, with 354 younger patients (age < 50 years) as controls. Ten easily obtainable clinical parameters were selected.

View Article and Find Full Text PDF
Article Synopsis
  • This study identified a subgroup of acute myeloid leukemia (AML) patients with an APL-like immunophenotype characterized by the absence of CD34 and HLA-DR, aiming to explore differences in clinical and molecular features between them and regular AML patients.
  • Out of 191 patients analyzed, 32 exhibited this specific immunophenotype and were found to have a higher risk of developing disseminated intravascular coagulation (DIC) and showed distinct molecular characteristics, including more frequent NPM1 mutations and higher WT1 gene expression.
  • Despite being in a favorable risk category based on some parameters, patients with the CD34HLA-DR immunophenotype experienced shorter overall survival, underscoring the need
View Article and Find Full Text PDF

Aims: Acute promyelocytic leukemia (APL) progresses quickly and often leads to early hemorrhagic death. Treatment with all-trans retinoic acid (ATRA) promotes differentiation of APL cells and clinical remission, making APL a potentially curable malignancy. Understanding how ATRA works may lead to new treatments for other types of leukemia.

View Article and Find Full Text PDF
Article Synopsis
  • Acute promyelocytic leukemia (APL) treatment has improved significantly with all-trans retinoic acid (ATRA) and arsenic, but issues like coagulation disorders and differentiation syndrome still pose risks, especially in children.
  • A multicenter randomized trial compares the effectiveness of ATRA plus chemotherapy (experimental group) against ATRA alone (control group) in treating pediatric patients with APL, focusing on reducing hyperleukocytosis and complications.
  • The goal is to determine whether adding chemotherapy during treatment induction is beneficial in lowering mortality rates among non-high-risk pediatric APL patients.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!